1 day Ago By ABMN Staff
Bank of New York Mellon Corp increased its stake in Genmab A/S ( NASDAQ:GMAB – Free Report ) by 4.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 70,171 shares of the company’s stock after buying an additional 3,283 shares during the quarter.
Bank of New York Mellon Corp’s holdings in Genmab A/S were worth $1,763,000 as of its most recent SEC filing. A number of other institutional investors also recently bought and sold shares of GMAB. Capital International Investors lifted its position in Genmab A/S by 7.
8% in the first quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock worth $130,805,000 after buying an additional 315,355 shares during the last quarter. First Trust Advisors LP lifted its position in shares of Genmab A/S by 16.
0% during the fourth quarter. First Trust Advisors LP now owns 1,270,095 shares of the company’s stock worth $40,440,000 after purchasing an additional 175,292 shares during the last quarter. Trexquant Investment LP bought a new stake in shares of Genmab A/S during the fourth quarter worth $4,875,000.
Harding Loevner LP lifted its position in shares of Genmab A/S by 2.7% during the fourth quarter. Harding Loevner LP now owns 3,289,895 shares of the company’s stock worth $97,569,000 after purchasing an additional 85,665 shares during the last quarter.
Finally, Campbell & CO Investment Adviser LLC bought a new stake in shares of Genmab A/S during the fourth quarter worth $1,879,000. 7.07% of the stock is currently owned by institutional investors.
Genmab A/S Trading Down 0.9 % Shares of Genmab A/S stock opened at $26.20 on Thursday.
The firm has a market cap of $17.33 billion, a P/E ratio of 21.83, a P/E/G ratio of 0.
81 and a beta of 0.99. Genmab A/S has a 12 month low of $24.
53 and a 12 month high of $37.97. The stock’s fifty day moving average price is $27.
29 and its 200-day moving average price is $28.02. Analyst Ratings Changes Several research firms have recently weighed in on GMAB.
Truist Financial decreased their target price on Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, September 9th.
HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research report on Friday, September 13th. Royal Bank of Canada upgraded Genmab A/S from a “sector perform” rating to an “outperform” rating in a research report on Monday, July 15th.
Morgan Stanley reiterated an “equal weight” rating and set a $31.00 target price on shares of Genmab A/S in a research report on Wednesday, September 11th. Finally, JPMorgan Chase & Co.
reiterated a “neutral” rating on shares of Genmab A/S in a research report on Tuesday, August 20th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $45.
20. Check Out Our Latest Stock Report on GMAB Genmab A/S Profile ( Free Report ) Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
See Also Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S ( NASDAQ:GMAB – Free Report ). Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.
com's FREE daily email newsletter ..
